Info: Read More
  • 中药标准品生产商,产品定制服务
  • 洛伐他汀

    Lovastatin

    洛伐他汀
    产品编号 CFN99961
    CAS编号 75330-75-5
    分子式 = 分子量 C24H36O5 = 404.54
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Diterpenoids
    植物来源 The secondary metabolite produced by filamentous fungi.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    洛伐他汀 CFN99961 75330-75-5 10mg QQ客服:1413575084
    洛伐他汀 CFN99961 75330-75-5 20mg QQ客服:1413575084
    洛伐他汀 CFN99961 75330-75-5 50mg QQ客服:1413575084
    洛伐他汀 CFN99961 75330-75-5 100mg QQ客服:1413575084
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Kazusa DNA Research Institute (Japan)
  • Pennsylvania State University (USA)
  • Guangzhou Institutes of Biomedicine and Health (China)
  • Martin Luther University of Halle-Wittenberg (Germany)
  • University of Leipzig (Germany)
  • National Research Council of Canada (Canada)
  • Shanghai University of TCM (China)
  • Ateneo de Manila University (Philippines)
  • Siksha O Anusandhan University (India)
  • Universidad de Ciencias y Artes de Chiapas (Mexico)
  • Macau University of Science and Technology (China)
  • University of Mysore (India)
  • Institute of Chinese Materia Medica (China)
  • Universidade Federal de Goias (UFG) (Brazil)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Food Res Int.2017, 96:40-45
  • Eur J Pharmacol.2020, 889:173589.
  • J Pharmaceut Biomed2020, 178:112894
  • Jour. of Stored Pro & Postharvest Res.2016, 7(3):32-36
  • Am J Chin Med.2016, 44(8):1719-1735
  • Molecules.2019, 24(2):E343
  • Biomed Pharmacother.2020, 131:110673.
  • Biomol Ther (Seoul).2019, 10.4062
  • J Sep Sci.2018, 41(9):1938-1946
  • Front Microbiol.2020, 11:583594.
  • Biomolecules.2021, 11(10):1537.
  • Journal of Third Military Medical University2018, 40(12):1073-1078
  • Food Chem.2019, 278:683-691
  • Front Pharmacol.2019, 10:1355
  • Food Funct.2022, 13(13):6923-6933.
  • Eur Rev Med Pharmacol Sci.2020, 24(9):5127-5139.
  • Polytechnic University of Catalonia2017, 105826
  • Sci Rep.2019, 9(1):18080
  • Korean J. Medicinal Crop Sci.2021, 29(6):425-433
  • Pest Manag Sci.2019, 75(9):2530-2541
  • J Basic Clin Physiol Pharmacol.2016, 27(1):1-8
  • Pharm Biol.2017, 55(1):360-366
  • American Association for Anatomy2020, doi: 10.1002.
  • ...
  • 生物活性
    Description: Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM in a cell-free assay, has a direct cellular effect independent of a cholesterol-lowering effect and delays the onset and progression of diabetic nephropathy. It has a potential application to treat PD via antioxidant effect, and it promotes fibrosis and epithelial to mesenchymal transition, by regulating the production of CCN2 in human gingival fibroblasts.
    Targets: HMG-CoA Reductase | CDK | GSK-3 | TGF-β/Smad
    In vitro:
    Neuroscience. 2015 May 21;294:14-20.
    Lovastatin suppresses the aberrant tau phosphorylation from FTDP-17 mutation and okadaic acid-induction in rat primary neurons.[Pubmed: 25770969]
    Statins are a class of cholesterol-lowering drugs and have been suggested therapeutic use for neurodegenerative diseases including Alzheimer's disease (AD). Our recent studies revealed a neuronal protective effect of lovastatin (LOV) from N-methyl-d-aspartic acid (NMDA) excitotoxicity. The neuroprotective mechanism of statins, however, is far unknown.
    METHODS AND RESULTS:
    Here we demonstrated that LOV suppressed the aberrant tau phosphorylation both from frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) mutation and okadaic acid (OA) induction in cultured rat primary neurons. The protective effect of LOV occurred at multiple pathological sites of tau protein, including Tyr181, Tyr231 Ser202/Tyr205, Tyr212/Ser214 and Ser396/Ser404. Further analysis revealed that the potential mechanism of the suppressive effect of LOV resulted from two aspects, activating OA-inhibited protein phosphatase 2A (PP2A) activity and attenuating OA-induced activity of tau kinases CDK5/P25 and CDK2/4, but not glycogen synthase kinase 3β (GSK3β).
    CONCLUSIONS:
    These findings give new insights into the molecular mechanism of LOV-mediated neuroprotective effect and provide experimental evidence for its therapeutic use in AD.
    In vivo:
    Am J Pathol. 2015 Apr 2.
    Prevention of Phenytoin-Induced Gingival Overgrowth by Lovastatin in Mice.[Pubmed: 25843680]
    Drug-induced gingival overgrowth is caused by the antiseizure medication phenytoin, calcium channel blockers, and ciclosporin. Characteristics of these drug-induced gingival overgrowth lesions differ.
    METHODS AND RESULTS:
    We evaluate the ability of a mouse model to mimic human phenytoin-induced gingival overgrowth and assess the ability of a drug to prevent its development. Lovastatin was chosen based on previous analyses of tissue-specific regulation of CCN2 production in human gingival fibroblasts and the known roles of CCN2 in promoting fibrosis and epithelial to mesenchymal transition. Data indicate that anterior gingival tissue overgrowth occurred in phenytoin-treated mice based on gross tissue observations and histomorphometry of tissue sections. Molecular markers of epithelial plasticity and fibrosis were regulated by phenytoin in gingival epithelial tissues and in connective tissues similar to that seen in humans. Lovastatin attenuated epithelial gingival tissue growth in phenytoin-treated mice and altered the expressions of markers for epithelial to mesenchymal transition. Data indicate that phenytoin-induced gingival overgrowth in mice mimics molecular aspects of human gingival overgrowth and that Lovastatin normalizes the tissue morphology and the expression of the molecular markers studied. Data are consistent with characterization of phenytoin-induced human gingival overgrowth in vivo and in vitro characteristics of cultured human gingival epithelial and connective tissue cells.
    CONCLUSIONS:
    Findings suggest that statins may serve to prevent or attenuate phenytoin-induced human gingival overgrowth, although specific human studies are required.
    J Am Soc Nephrol. 2000 Jan;11(1):80-7.
    Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells.[Pubmed: 10616843]
    Diabetic nephropathy is a leading cause of end-stage renal disease and is characterized by excessive deposition of extracellular matrix (ECM) proteins in the glomeruli. Transforming growth factor-beta (TGF-beta) is the major mediator of excessive accumulation of ECM proteins in diabetic nephropathy through upregulation of genes encoding ECM proteins as well as downregulation of genes for ECM-degrading enzymes. It has been shown that lovastatin, an inhibitor of 3-hydroxy3-methylglutaryl CoA reductase, delays the onset and progression of different models of experimental nephropathy.
    METHODS AND RESULTS:
    To evaluate the effect of lovastatin on the development and progression of diabetic nephropathy, streptozotocin-induced diabetic rats were studied for 12 mo. In untreated diabetic rats, there were significant increases in blood glucose, urine albumin excretion, kidney weight, glomerular volume, and TGF-beta1 mRNA expression in the glomeruli compared with normal control rats treated with citrate buffer only. Treatment with lovastatin in diabetic rats significantly suppressed the increase in urine albumin excretion, kidney weight, glomerular volume, and TGF-beta1 mRNA expression despite high blood glucose levels. To elucidate the mechanisms of the renal effects of lovastatin, rat mesangial cells were cultured under control (5.5 mM) or high (30 mM) glucose with lovastatin alone, mevalonate alone, or with both. Under high glucose, TGF-beta1 and fibronectin mRNA and proteins were upregulated. These high glucose-induced changes were suppressed by lovastatin (10 micro/M) and nearly completely restored by mevalonate (100 microM).
    CONCLUSIONS:
    These results suggest that lovastatin has a direct cellular effect independent of a cholesterol-lowering effect and delays the onset and progression of diabetic nephropathy, at least in part, through suppression of glomerular expression of TGF-beta1.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.4719 mL 12.3597 mL 24.7194 mL 49.4389 mL 61.7986 mL
    5 mM 0.4944 mL 2.4719 mL 4.9439 mL 9.8878 mL 12.3597 mL
    10 mM 0.2472 mL 1.236 mL 2.4719 mL 4.9439 mL 6.1799 mL
    50 mM 0.0494 mL 0.2472 mL 0.4944 mL 0.9888 mL 1.236 mL
    100 mM 0.0247 mL 0.1236 mL 0.2472 mL 0.4944 mL 0.618 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    美伐他汀; Mevastatin CFN90426 73573-88-3 C23H34O5 = 390.51 20mg QQ客服:2159513211
    洛伐他汀; Lovastatin CFN99961 75330-75-5 C24H36O5 = 404.54 20mg QQ客服:215959384
    辛伐他汀,斯伐他汀; Simvastatin CFN90427 79902-63-9 C25H38O5 = 418.56 20mg QQ客服:215959384
    三白草酮; Sauchinone CFN90153 177931-17-8 C20H20O6 = 356.36 20mg QQ客服:2159513211
    Fischeria A; Fischeria A CFN92879 221456-63-9 C19H28O2 = 288.4 5mg QQ客服:215959384
    Kongensin A; Kongensin A CFN97452 885315-96-8 C22H30O5 = 374.5 5mg QQ客服:1457312923
    3,10-二羟基-5,11-二薄荷二烯-4,9-二酮; 3,10-Dihydroxy-5,11-dielmenthadiene-4,9-dione CFN99078 106623-23-8 C20H28O4 = 332.4 5mg QQ客服:1457312923
    因香酚; Incensole CFN93208 22419-74-5 C20H34O2 = 306.5 20mg QQ客服:3257982914
    醋酸因香酚; Incensole acetate CFN93207 34701-53-6 C22H36O3 = 348.5 20mg QQ客服:1457312923

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产